• Enopace Biomedical

  Led · Equity · Feb 2013

  Enopace Biomedical is an early-stage medical device company developing a miniature, implantable endovascular micro-stimulator and neuromodulation system intended to increase cardiac efficiency by reducing left ventricular workload in heart failure patients. The technology is being positioned to expand device-based therapy options for the large unmet need of heart failure. The company was founded in 2008, is based in Caesarea, Israel, and is led by CEO Amir Dagan. Enopace was seeded and is owned by Rainbow Medical, which has backed multiple med‑tech ventures. Sorin Group executed an initial investment in October 2011 and is now providing further financing to support ongoing development and testing. The current financing is structured as a minority investment with milestone-triggered follow‑on funding and includes an exclusive option for Sorin to acquire the company in the future. Enopace Biomedical is an early-stage medical device company developing a minimally invasive, implantable neurostimulation system intended to increase cardiac efficiency by reducing left ventricular workload in congestive heart failure patients. The device targets an unmet need in heart failure treatment, including patient segments not served by cardiac resynchronization therapy. Sorin Group’s $7 million investment will finance the company’s initial clinical studies and ongoing product development. Rainbow Medical founded and seeded Enopace in 2008 and remains an investor. The company is led by CEO Amir Dagan and is based in Caesarea, Israel. No revenue or user metrics are disclosed in the article.

• Cardiosolutions

  Led · Equity · Jul 2012

  Cardiosolutions develops the Mitra-Spacer™, a proprietary percutaneous implant designed to fill the void from a dilated valvular annulus and provide a sealing surface for diseased mitral valve leaflets. The company has also developed the Dexterity™ Steerable Introducer System for advancement and delivery of cardiovascular catheters. Its technology targets patients with moderate to severe mitral regurgitation, including many who are high-risk for surgery or currently untreated. Cardiosolutions was incubated within and spun out of STD Med in 2006 and is based in West Bridgewater, Massachusetts. The company is focused on ongoing product development and clinical testing to advance its minimally invasive therapy toward clinical use. Recent financing will support those development and clinical activities and positions the company for potential strategic partnership or exit.

No current team members are available.